Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation.
BACKGROUND
This 7-year, prospective, matched-cohort, clinical study evaluated the effects of intramuscular depot medroxyprogesterone acetate (DMPA) (150 mg/mL) on bone mineral density (BMD) in women aged 25-35 years.


METHODS
Bone mineral density changes in new DMPA-IM users (n=248) were compared with those in women using nonhormonal contraception (n=360) for up to 240 weeks of treatment and 96 weeks of posttreatment follow-up (in subjects receiving >or=1 dose).


RESULTS
At week 240 of treatment, mean percentage changes from baseline in DMPA-IM vs. nonhormonal subjects were: -5.16% (n=21) vs. +0.19% (n=65), total hip (p<.001); -5.38% (n=33) vs. +0.43% (n=105), lumbar spine (p<.001). At week 96 posttreatment, these values were: -0.20% (n=25) vs. +0.84% (n=43), total hip (p=.047); -1.19% (n=41) vs. +0.47% (n=66), lumbar spine (p=.017).


CONCLUSIONS
These results show BMD declines during DMPA-IM use; following discontinuation, significant increases in BMD occur through 96 weeks posttreatment.
Kaunitz
Andrew M
AM
Department of Obstetrics and Gynecology, University of Florida Health Science Center, Jacksonville, FL 32209, USA. andrew.kaunitz@jax.ufl.edu
Miller
Paul D
PD
Rice
Valerie Montgomery
VM
Ross
Doug
D
McClung
Michael R
MR
D000328:Adult; D001835:Body Weight; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000378:metabolism; D015331:Cohort Studies; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects*; D015675:Osteocalcin / Q000097:blood; D011446:Prospective Studies
D003271:Contraceptive Agents, Female; D008055:Lipids; D015675:Osteocalcin; D017258:Medroxyprogesterone Acetate